


Define an HBV cure

Functionally (practical):


- Sustained, off drug response (loss of viremia and antigenemia
 <u>Clinically:</u>
- Return an individual to the risk of death and disease due to liver disease to that of an age and gender adjusted uninfected individual


- Block, Gish et al, AVR, 2015
- Liang, Block et al, Hepatology, 2016

Categories of HBV therapeutics Direct Acting Antivirals (DAA) Indirect (Host) Acting Antivirals (Host)














Tenofovir approved in US for HBV, in 2008, but not yet approved in China for HBV

All are Direct Acting Antivirals (DAA)

Functional cures do occur with current therapeutics, although rarely

JOURNAL OF HEPATOLOGY

Table 2. Results of main studies for the treatment of HBeAg-positive chronic hepatitis B at 6 months following 12 months (48 or 52 weeks) of pegylated interferon alpha (PEG-IFN) and at 12 months (48 or 52 weeks) of nucleos(t)ide analogue therapy.

	PEG-IFN		Nucleoside analogues			Nucleotide analogues	
	PEG-IFN-2a	PEG-IFN-2b	Lamivudine	Telbivudine	Entecavir	Adefovir	Tenofovir
Dose*	180 µg	100 µg	100 mg	600 mg	0.5 mg	10 mg	245 mg
[Ref.]	[63]	[64]	[63, 65-68]	[68]	[67]	[69, 70]	[70]
Anti-HBe seroconversion (%)	32	29	16-18	22	21	12-18	21
HBV DNA <60-80 IU/ml (%)	14	7	36-44	60	67	13-21	76
ALT normalisation# (%)	41	32	41-72	77	68	48-54	68
HBsAg loss (%)	3	7	0-1	0.5	2	0	3


*PEG-IFN were given as percutaneous injections once weekly and nucleos(t)ide analogues as oral tablets once daily.

*The definition of ALT normalisation varied among different trials (i.e. decrease of ALT to ≤1.25-times the upper limit of normal (ULN) in the entecavir or ≤1.3-times the ULN in the telbivudine trial).

Journal of Hepatology 2012 vol. 57 | 167-185

Failure to cure with NUCs is because

Nests of infected cells (cccDNA containing) remain; HBsAg continues to be made: T cells exhausted B cells: no detectable HBsAb





- Something new that complements current compounds
- Different mechanism DAA

+

• An immuno-enhancer

Categories of Anti-HBV Strategies

Direct Acting Antivirals

- <u>In Use</u>
 - Polymerase
- <u>Potential</u>
 - RNaseH
 - RNAi
 - Capsid inhibitors
 - sAg
 - eAg
 - Virus attachment
 - CRISPR/CAS

In-Direct Acting Antivirals


Immuno-modulatory


- In Use
 - Interferons
- Potential
 - Therapeutic vaccines
 - PD-1 blockade
 - Toll R agonists
 - STING, other innate defense
 - Interleukins, other cytokines

Essential host functions

- <u>In Use</u>
 - None for HBV
- <u>Potential</u>
 - Epigentic modifiers
 - Entry
 - Morphogenesis
 - Exit
 - Glycan processing

The HBV Therapeutic Development Landscape as of Jan, 2016





Block & Liang, 2016

Pol inhibitors:

o J

Golgi

ER

5/000


Ø MVI


Cytoplas

Ø


O cccD#


Nucleus







cccDNA: "natural" source of all viral gene products









Repress cccDNA, and repress all natural gene product




But cccDNA is a small, tough target






Block & Guo, 2015, Gastroeneterology

But some HBV DNA is "integrated" and not free cccDNA, and thus might be missed by drugs acting on cccDNA



RNAi transcript inhibition




In development: <u>Antisense:</u> (Ionis/GSK3228836)*

<u>shRNA:</u> Alnylam (ALNHBV)* Arrowhead (ARC520,521)* Arbutus (ARB 1467,1740)* Benitec


*Human Trials

RNAi / sh RNA leads to degradation of HBV RNA transcripts from cccDNA and integrated DNA

ant a mit warmal



RNAi: Complete shut down:




Entry Inhibitors

Taskin of the line has


Entry Inhibitor (oilgopeptide) MyrcludexB* Human Trials


and it is the sealer





Entry Inhibitors

Tastin on bal










sAg inhibition: antiviral, anti-antigenemic, and ?immuno restoration



Hepatitis Delta Virus

• Needs co-infection with HBV

• Mycludex B and Eiger's Lornafarnib in human trials for HDV

Adaptive & Innate host Adaptive defense

T cells (exhausted) B cells (No detectable **Indirect treatment** Antibody to HBs) macrophage Two cell chamber transfer Awaken, stimulate RAW 264.7 cells

Tankin or in the line

Gilead GS4774* Inovio Roche INO1800* Altimmune* Transgene TG1050*



Innate


Gilead Toll GS9620* Roche Toll RO6884018* SpringBank RIGI SB9200* Arbutus STING A **Contravir Cyclophil CPI421**

*Human Trials


hepatocyte-derived cells **HBV HBV**

Inhibiting the virus life cycle at any step should be equal in eliminating infection

Break HBV down in to at least 12 different "assayable", "targetable" steps Grouped in to 6, here...



Current Guidelines



Source: Gerlich, W. 2013. Virology Journal, 10:239

Hepatitis B Foundation Goal

• No one will die from HBV by 2030

• A cure is possible, necessary, and expected



Hepatitis B Foundation Cause for a Cure



